Draupnir Holding successfully places shares of PolyPeptide Group
Draupnir Holding, global provider of business decisioning data and analytics, sells 1,500,000 existing ordinary shares in PolyPeptide Group in private placements to institutional investors by way of an accelerated bookbuilding process.
The shares, which represent approximately 4.5 per cent. of PolyPeptide’s share capital, were placed at a price of CHF 114 per share, raising aggregate gross proceeds of CHF 171 million for Draupnir. Following settlement of the placement on 12 November 2021, Draupnir continues to hold approximately 55.5 per cent of PolyPeptide’s share capital.
Credit Suisse and Morgan Stanley Europe SE acted as joint bookrunners in connection with the offering.
Niederer Kraft Frey advised Draupnir Holding with a team led by partner Philippe Weber (corporate/capital market, pictured), working with senior associate Franziska Albers–Schönberg.
